A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Jean-Pascal Machiels; Ramon Salazar; Sylvie Rottey; Ignacio Duran; Luc Dirix; Karen Geboes; Christine Wilkinson-Blanc; Gillian Pover; Simon Alvis; Brian Champion; Kerry Fisher; Hilary McElwaine-Johnn; John Beadle; Emiliano Calvo

doi:10.1186/s40425-019-0510-7

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

XML

Research Article

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Machiels J, Salazar R, Rottey S, et al

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Journal for ImmunoTherapy of Cancer 2019;7:20. doi: 10.1186/s40425-019-0510-7

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password